Jung-Mao Hsu

13.6k total citations · 7 hit papers
56 papers, 6.1k citations indexed

About

Jung-Mao Hsu is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Jung-Mao Hsu has authored 56 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 23 papers in Oncology and 14 papers in Immunology. Recurrent topics in Jung-Mao Hsu's work include Cancer Immunotherapy and Biomarkers (9 papers), Immunotherapy and Immune Responses (6 papers) and Galectins and Cancer Biology (4 papers). Jung-Mao Hsu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Immunotherapy and Immune Responses (6 papers) and Galectins and Cancer Biology (4 papers). Jung-Mao Hsu collaborates with scholars based in Taiwan, United States and China. Jung-Mao Hsu's co-authors include Mien‐Chie Hung, Hirohito Yamaguchi, Weiya Xia, Jennifer L. Hsu, Chia‐Wei Li, Gabriel N. Hortobágyi, Chun‐Te Chen, Chao‐Kai Chou, Wenhao Yang and Yongkun Wei and has published in prestigious journals such as Science, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Jung-Mao Hsu

56 papers receiving 6.0k citations

Hit Papers

PARP Inhibitor Upregulates PD-L1 Expression and Enhances ... 2017 2026 2020 2023 2017 2021 2018 2022 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
    2017 768 citations Shiping Jiao, Weiya Xia et al. Clinical Cancer Research profile →
  2. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
    2021 405 citations Ri‐Yao Yang, Linlin Sun et al. profile →
  3. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
    2018 354 citations Jung-Mao Hsu, Weiya Xia et al. profile →
  4. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
    2022 347 citations Hirohito Yamaguchi, Jung-Mao Hsu et al. profile →
  5. TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
    2021 255 citations Zhou Jiang, Seung-Oe Lim et al. Journal of Clinical Investigation profile →
  6. Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity
    2021 216 citations Junwei Hou, Jung-Mao Hsu et al. Molecular Cell profile →
  7. Advances and prospects of biomarkers for immune checkpoint inhibitors
    2024 50 citations Hirohito Yamaguchi, Jung-Mao Hsu et al. Cell Reports Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jung-Mao Hsu Taiwan 35 3.5k 3.0k 1.6k 1.0k 730 56 6.1k
Moorthy P. Ponnusamy United States 43 3.4k 1.0× 2.3k 0.8× 998 0.6× 1.0k 1.0× 632 0.9× 113 5.4k
Elaine M. Hurt United States 35 3.1k 0.9× 2.4k 0.8× 2.0k 1.2× 1.0k 1.0× 638 0.9× 59 6.3k
Daniel J. Lindner United States 41 3.2k 0.9× 1.5k 0.5× 1.3k 0.8× 1.1k 1.1× 430 0.6× 133 5.4k
Wei‐Zhong Wu China 41 3.5k 1.0× 2.1k 0.7× 1.0k 0.6× 1.9k 1.9× 470 0.6× 107 5.7k
Junnian Zheng China 38 3.6k 1.0× 1.9k 0.6× 1.2k 0.8× 1.7k 1.7× 629 0.9× 201 5.8k
Hasan Körkaya United States 32 3.7k 1.1× 4.1k 1.4× 1.1k 0.7× 1.9k 1.8× 496 0.7× 63 7.1k
Surinder K. Batra United States 41 2.6k 0.7× 1.7k 0.6× 822 0.5× 675 0.7× 596 0.8× 82 4.4k
Jeffrey E. Green United States 41 3.7k 1.1× 2.7k 0.9× 679 0.4× 1.8k 1.8× 752 1.0× 103 6.4k
Anping Li China 35 2.7k 0.8× 1.9k 0.6× 1.2k 0.7× 1.2k 1.2× 668 0.9× 54 4.9k
Martin R. Sprick Germany 31 4.0k 1.1× 3.6k 1.2× 1.3k 0.8× 2.0k 2.0× 438 0.6× 58 6.6k

Countries citing papers authored by Jung-Mao Hsu

Since Specialization
Citations

This map shows the geographic impact of Jung-Mao Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jung-Mao Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jung-Mao Hsu more than expected).

Fields of papers citing papers by Jung-Mao Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jung-Mao Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jung-Mao Hsu. The network helps show where Jung-Mao Hsu may publish in the future.

Co-authorship network of co-authors of Jung-Mao Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Jung-Mao Hsu. A scholar is included among the top collaborators of Jung-Mao Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jung-Mao Hsu. Jung-Mao Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hsu, Jung-Mao, et al.. (2025). MTAP deficiency confers resistance to cytosolic nucleic acid sensing and STING agonists. Science. 390(6769). eadl4089–eadl4089. 1 indexed citations
2.
Yamaguchi, Hirohito, Jung-Mao Hsu, Linlin Sun, Shao‐Chun Wang, & Mien‐Chie Hung. (2024). Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Reports Medicine. 5(7). 101621–101621. 50 indexed citations breakdown →
3.
Sun, Xian Wen, Wei‐Jan Wang, Ri‐Yao Yang, et al.. (2023). Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity. International Journal of Biological Sciences. 19(14). 4644–4656. 8 indexed citations
4.
Zhao, Xixi, Yongkun Wei, Yu‐Yi Chu, et al.. (2022). Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function. Cancer Research. 82(11). 2185–2195. 36 indexed citations
5.
Jiang, Zhou, Seung-Oe Lim, Meisi Yan, et al.. (2021). TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. Journal of Clinical Investigation. 131(8). 255 indexed citations breakdown →
6.
Hou, Junwei, Jung-Mao Hsu, & Mien‐Chie Hung. (2021). Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity. Molecular Cell. 81(22). 4579–4590. 216 indexed citations breakdown →
7.
Qiu, Yufan, Ri‐Yao Yang, Chunxiao Liu, et al.. (2021). Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. Oncogene. 40(31). 4992–5001. 112 indexed citations
8.
Sun, Linlin, Chia-Wei Li, Ezra M. Chung, et al.. (2020). Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. Cancer Research. 80(11). 2298–2310. 133 indexed citations
9.
Wang, Yuhan, Linlin Sun, Ri‐Yao Yang, et al.. (2020). Abstract 6527: Targeting glycosylated PD-1 induces potent anti-tumor immunity. Cancer Research. 80(16_Supplement). 6527–6527. 2 indexed citations
10.
Li, Hui, Chia‐Wei Li, Xiaoqiang Li, et al.. (2019). MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology. 156(6). 1849–1861.e13. 154 indexed citations
11.
Jiao, Shiping, Weiya Xia, Hirohito Yamaguchi, et al.. (2017). PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clinical Cancer Research. 23(14). 3711–3720. 768 indexed citations breakdown →
12.
Chou, Chao‐Kai, Heng‐Huan Lee, Heng‐Huan Lee, et al.. (2014). mMAPS: A Flow-Proteometric Technique to Analyze Protein-Protein Interactions in Individual Signaling Complexes. Science Signaling. 7(315). rs1–rs1. 7 indexed citations
13.
Chen, Chun‐Te, Yi Du, Hirohito Yamaguchi, et al.. (2012). Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer. Molecular Cancer Therapeutics. 11(10). 2212–2221. 21 indexed citations
14.
Su, Jen-Liang, Xiaoyun Cheng, Hirohito Yamaguchi, et al.. (2011). FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. Cancer Research. 71(21). 6878–6887. 39 indexed citations
15.
Xia, Weiya, Xiaoming Xie, Chi-Hong Chao, et al.. (2011). EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin Signaling. Cancer Cell. 19(1). 86–100. 328 indexed citations
16.
Hsu, Jung-Mao, Chun‐Te Chen, Chao‐Kai Chou, et al.. (2011). Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nature Cell Biology. 13(2). 174–181. 195 indexed citations
17.
Yen, Chia-Jui, Julie Izzo, Dung‐Fang Lee, et al.. (2008). Bile Acid Exposure Up-regulates Tuberous Sclerosis Complex 1/Mammalian Target of Rapamycin Pathway in Barrett's-Associated Esophageal Adenocarcinoma. Cancer Research. 68(8). 2632–2640. 49 indexed citations
18.
Ding, Qingqing, Longfei Huo, Jer-Yen Yang, et al.. (2008). Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer. Cancer Research. 68(15). 6109–6117. 163 indexed citations
19.
Chen, Tzong-Yueh, Chang-Tze Ricky Yu, Jung-Mao Hsu, et al.. (2005). Identification of V23RalA-Ser194 as a Critical Mediator for Aurora-A-induced Cellular Motility and Transformation by Small Pool Expression Screening. Journal of Biological Chemistry. 280(10). 9013–9022. 81 indexed citations
20.
Hsu, Jung-Mao & Bacon F. Chow. (1960). Effect of Thiamine Deficiency on Glutathione Contents of Erythrocytes and Tissues in the Rat. Experimental Biology and Medicine. 104(2). 178–180. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Moorthy P. Ponnusamy Breakdown of academic impact, for papers by Elaine M. Hurt Breakdown of academic impact, for papers by Daniel J. Lindner Breakdown of academic impact, for papers by Wei‐Zhong Wu Breakdown of academic impact, for papers by Junnian Zheng Breakdown of academic impact, for papers by Hasan Körkaya Breakdown of academic impact, for papers by Surinder K. Batra Breakdown of academic impact, for papers by Jeffrey E. Green Breakdown of academic impact, for papers by Anping Li Breakdown of academic impact, for papers by Martin R. Sprick
Rankless by CCL
2026